AAAAAA

   
Results: 1-10 |
Results: 10
TIGHT-BINDING INFLUENCING THE FUTURE OF PHARMACOKINETICS
Authors: BROCKMEIER D
Citation: D. Brockmeier, TIGHT-BINDING INFLUENCING THE FUTURE OF PHARMACOKINETICS, Methods and findings in experimental and clinical pharmacology, 20(6), 1998, pp. 505-516
A DISTRIBUTION STUDY OF CYP1A2 PHENOTYPES AMONG SMOKERS AND NONSMOKERS IN A COHORT OF HEALTHY CAUCASIAN VOLUNTEERS
Authors: SCHRENK D BROCKMEIER D MORIKE K BOCK KW EICHELBAUM M
Citation: D. Schrenk et al., A DISTRIBUTION STUDY OF CYP1A2 PHENOTYPES AMONG SMOKERS AND NONSMOKERS IN A COHORT OF HEALTHY CAUCASIAN VOLUNTEERS, European Journal of Clinical Pharmacology, 53(5), 1998, pp. 361-367
INHIBITION OF FIBRINOGEN BINDING TO GLYCOPROTEIN IIB IIIA AS A NOVEL BIOASSAY FOR THE DETERMINATION OF FIBRINOGEN RECEPTOR ANTAGONISTIC PLASMA EQUIVALENTS/
Authors: JABLONKA B BROCKMEIER D JUST M MAAS J SCHMIDT D SEIBERTGRAFE M STILZ U
Citation: B. Jablonka et al., INHIBITION OF FIBRINOGEN BINDING TO GLYCOPROTEIN IIB IIIA AS A NOVEL BIOASSAY FOR THE DETERMINATION OF FIBRINOGEN RECEPTOR ANTAGONISTIC PLASMA EQUIVALENTS/, Naunyn-Schmiedeberg's archives of pharmacology, 356(4), 1997, pp. 17-17
TIGHT-BINDING OF RAMIPRILAT TO ACE - CONSEQUENCES FOR PHARMACOKINETICAND PHARMACODYNAMIC MEASUREMENTS. (VOL 33, PG 631, 1995)
Authors: BROCKMEIER D
Citation: D. Brockmeier, TIGHT-BINDING OF RAMIPRILAT TO ACE - CONSEQUENCES FOR PHARMACOKINETICAND PHARMACODYNAMIC MEASUREMENTS. (VOL 33, PG 631, 1995), International journal of clinical pharmacology and therapeutics, 34(2), 1996, pp. 92-92
SITE-DEPENDENT SMALL-INTESTINAL ABSORPTION OF THE ACE-INHIBITOR RAMIPRIL
Authors: GRAMATTE T BROCKMEIER D HERBIG U SEIBERTGRAFE M
Citation: T. Gramatte et al., SITE-DEPENDENT SMALL-INTESTINAL ABSORPTION OF THE ACE-INHIBITOR RAMIPRIL, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 58-58
TIGHT-BINDING OF RAMIPRILAT TO ACE - CONSEQUENCES FOR PHARMACOKINETICAND PHARMACODYNAMIC MEASUREMENTS
Authors: BROCKMEIER D
Citation: D. Brockmeier, TIGHT-BINDING OF RAMIPRILAT TO ACE - CONSEQUENCES FOR PHARMACOKINETICAND PHARMACODYNAMIC MEASUREMENTS, International journal of clinical pharmacology and therapeutics, 33(12), 1995, pp. 631-638
THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, ANDPARACETAMOL AS PROBES
Authors: BOCK KW SCHRENK D FORSTER A GRIESE EU MORIKE K BROCKMEIER D EICHELBAUM M
Citation: Kw. Bock et al., THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, ANDPARACETAMOL AS PROBES, Pharmacogenetics, 4(4), 1994, pp. 209-218
CHARACTERIZATION OF CYCLOSPORINE-A UPTAKE IN HUMAN ERYTHROCYTES
Authors: REICHEL C VANFALKENHAUSEN M BROCKMEIER D DENGLER HJ
Citation: C. Reichel et al., CHARACTERIZATION OF CYCLOSPORINE-A UPTAKE IN HUMAN ERYTHROCYTES, European Journal of Clinical Pharmacology, 46(5), 1994, pp. 417-419
SUBSTRATE AFFINITY OF THE PROTEIN-TYROSINE KINASE PP60(C-SRC) IS INCREASED ON THROMBIN STIMULATION OF HUMAN PLATELETS
Authors: LIEBENHOFF U BROCKMEIER D PRESEK P
Citation: U. Liebenhoff et al., SUBSTRATE AFFINITY OF THE PROTEIN-TYROSINE KINASE PP60(C-SRC) IS INCREASED ON THROMBIN STIMULATION OF HUMAN PLATELETS, Biochemical journal, 295, 1993, pp. 41-48
MULTIPLE-DOSE PHARMACOKINETICS OF RAMIPRIL IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE
Authors: HEINTZ B VERHO M BROCKMEIER D LUCKEL G MAIGATTER S SIEBERTH HG RANGOONWALA B BENDER N
Citation: B. Heintz et al., MULTIPLE-DOSE PHARMACOKINETICS OF RAMIPRIL IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE, Journal of cardiovascular pharmacology, 22, 1993, pp. 190000036-190000042
Risultati: 1-10 |